Stability and sterility of recombinant tissue plasminogen activator at -30°C

Lancet

Volumn 355, Issue 9222, 2000, Pages 2221-2222

  Wiernikowski, John T ^a   Crowther, Mark ^b   Clase, Catherine M ^c   Ingram, Alistair ^b   Andrew, Maureen ^d   Chan, Anthony K C ^d  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLASMINOGEN ACTIVATOR; STREPTOKINASE; UROKINASE;

CENTRAL VENOUS CATHETERIZATION; DRUG STABILITY; LETTER; PRIORITY JOURNAL;

EID: 0034709732     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02411-9     Document Type: Article

References (4)

1. Information alert for prescribers, urokinase (Abbott Laboratories), January 25, 1999. 1999;US Food and Drug Administration, Bethesda, MD.
2. Cairns J.A., Kennedy J.W., Fuster V. Coron Thrombolysis Chest. 114:1998;634S-657S.
3. Haire W.D., Atkinson J.B., Stephens L.C., Kotulak G.D. Urokinase vs r-TPA in thrombosed central venous catheters. a double blind randomized trial Thromb Hemost. 72:1994;543-547.
4. Allen LV. Plasminogen activator. US Pharmacist, July, 1992: 64-72.